Crosstalk between antibiotic resistance and virulence in Pseudomonas aeruginosa

Reviews and Research in Medical Microbiology

Volumn 16, Issue 4, 2005, Pages 155-161

  Gustafsson, Ingegerd ^a   Martínez, José L ^b  

^a HALMSTAD HOSPITAL   (Sweden)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Antibiotic resistance; Bacterial virulence; Multidrug efflux pumps; Multidrug resistance; Pseudomonas aeruginosa; Quorum sensing; Type III secretion

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIAL VIRULENCE; BURN INFECTION; CANCER; CYSTIC FIBROSIS; GENE CONTROL; HUMAN; IMMUNE DEFICIENCY; MULTIDRUG RESISTANCE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; REGULATORY MECHANISM; REVIEW; RISK FACTOR;

EID: 26044479685     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.revmedmi.0000184742.98550.7b     Document Type: Review

References (54)

1. Mahajan-Miklos S, Rahme LG, Ausubel FM. Elucidating the molecular mechanisms of bacterial virulence using non-mammalian hosts. Mol Microbiol 2000; 37:981-988.
2. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. Science 1995; 268:1899-1902.
3. Morales G, Wiehlmann L, Gudowius P, van Delden C, Tummler B, Martinez JL, et al. Structure of Pseudomonas aeruginosa populations analyzed by single nucleotide polymorphism and pulsed-field gel electrophoresis genotyping. J Bacteriol 2004; 186:4228-4237.
4. Wolfgang MC, Kulasekara BR, Liang X, Boyd D, Wu K, Yang Q, et al. Conservation of genome content and virulence determinants among clinical and environmental isolates of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2003; 100:8484-8489.
5. Alonso A, Rojo F, Martinez JL. Environmental and clinical isolates of Pseudomonas aeruginosa show pathogenic and biodegradative properties irrespective of their origin. Environ Microbiol 1999; 1:421-430.
6. Liang X, Pham XQ, Olson MV, Lory S. Identification of a genomic island present in the majority of pathogenic isolates of Pseudomonas aeruginosa. J Bacteriol 2001; 183:843-853.
7. Smith RS, Iglewski BH. P. aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol 2003; 6:56-60.
8. Alonso A, Campanario E, Martinez JL. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 1999; 145:2857-2862.
9. Lee K, Lim JB, Yum JH, Yong D, Chong Y, Kim JM. Livermore DM. bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002; 46:1053-1058.
10. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2:489-493.
11. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002; 15: 647-679.
12. Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996; 15:402-405.
13. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005; 11:68-74.
14. Benveniste R, Davies J. Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. Proc Natl Acad Sci USA 1973; 70:2276-2280.
15. Pang Y, Brown BA, Steingrube VA, Wallace RJ Jr, Roberts MC. Tetracycline resistance determinants in Mycobacterium and Streptomyces species. Antimicrob Agents Chemother 1994; 38:1408-1412.
16. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64:159-204.
17. Saier MH Jr, Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. FASEB J 1998; 12:265-274.
18. Mahajan-Miklos S, Tan MW, Rahme LG, Ausubel FM. Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model. Cell 1999; 96:47-56.
19. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, et al. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med 2002; 196:109-118.
20. Henke JM, Bassler BL. Bacterial social engagements. Trends Cell Biol 2004; 14:648-656.
21. Erickson DL, Endersby R, Kirkham A, Stuber K, Vollman DD, Rabin HR, et al. Pseudomonas aeruginosa quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. Infect Immun 2002; 70:1783-1790.
22. Duan K, Dammel C, Stein J, Rabin H, Surette MG. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol 2003; 50:1477-1491.
23. Pearson JP, Feldman M, Iglewski BH, Prince A. Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infect Immun 2000; 68:4331-4334.
24. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003; 22:3803-3815.
25. Pearson JP, Van Delden C, Iglewski BH. Active efflux and diffusion are involved in transport of Pseudomonas aeruginosa cell-to-cell signals. J Bacteriol 1999; 181:1203-1210.
26. Kohler T, van Delden C, Curty LK, Hamzehpour MM, Pechere JC. Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa. J Bacteriol 2001; 183:5213-5222.
27. Ziha-Zarifi I, Lianes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43:287-291.
28. Grkovic S, Brown MH, Skurray RA. Regulation of bacterial drug export systems. Microbiol Mol Biol Rev 2002; 66:671-701.
29. Sanchez P, Linares JF, Ruiz-Diez B, Campanario E, Navas A, Baquero F, et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002; 50:657-664.
30. Ruiz-Diez B, Sanchez P, Baquero F, Martinez JL, Navas A. Differential interactions within the Caenorhabditis elegans-Pseudomonas aeruginosa pathogenesis model. J Theor Biol 2003; 225:469-476.
31. Cosson P, Zulianello L, Join-Lambert O, Faurisson F, Gebbie L, Benghezal M, et al. Pseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host system. J Bacteriol 2002; 184:3027-3033.
32. Linares JF, Lopez JA, Camafeita E, Albar JP, Rojo F, Martinez JL. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. J Bacteriol 2005; 187:1384-1391.
33. Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998; 62:379-433.
34. Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 2001; 9:50-52.
35. De Vos D, De Chial M, Cochez C, Jansen S, Tummler B, Meyer JM, et al. Study of pyoverdine type and production by Pseudomonas aeruginosa isolated from cystic fibrosis patients: prevalence of type II pyoverdine isolates and accumulation of pyoverdine-negative mutations. Arch Microbiol 2001; 175:384-388.
36. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS, Lory S. A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa. Dev Cell 2004; 7:745-754.
37. Barbosa TM, Levy SB. Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of Mar A. J Bacteriol 2000; 182:3467-3474.
38. Juhas M, Wiehlmann L, Huber B, Jordan D, Lauber J, Salunkhe P, et al. Global regulation of quorum sensing and virulence by VqsR in Pseudomonas aeruginosa. Microbiology 2004; 150:831-841.
39. Aendekerk S, Diggle SP, Song Z, Hojby N, Cornells P, Williams P, et al. The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication. Microbiology 2005; 151:1113-1125.
40. Aendekerk S, Ghysels B, Cornells P, Baysse C. Characterization of a new efflux pump, MexGHI-OpmD, from Pseudomonas aeruginosa that confers resistance to vanadium. Microbiology 2002; 148:2371-2381.
41. Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004; 42:5229-5237.
42. Lee VT, Smith RS, Tummler B, Lory S. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect Immun 2005; 73:1695-1705.
43. Moss J, Ehrmantraut ME, Banwart BD, Frank DW, Barbieri JT. Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus. Infect Immun 2001; 69:1185-1188.
44. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2003; 23:916-924.
45. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44:710-712.
46. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000; 44:1771-1777.
47. Oliver A, Levin BR, Juan C, Baquero F, Blazquez J. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 2004; 48:4226-4233.
48. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-1254.
49. Gustafsson I, Sjolund M, Torell E, Johannesson M, Engstrand L, Cars O, et al. Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother 2003; 52:645-650.
50. Gutierrez O, Juan C, Perez JL, Oliver A. Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob Agents Chemother 2004; 48:3573-3575.
51. Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005; 49:2276-2282.
52. Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005; 104:205-212.
53. Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004; 25:825-831.
54. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38:670-677.